<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02180100</url>
  </required_header>
  <id_info>
    <org_study_id>PKUSH-GNY-2013-01</org_study_id>
    <nct_id>NCT02180100</nct_id>
  </id_info>
  <brief_title>Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis</brief_title>
  <official_title>A Randomized, Parallel-group Study of Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Shenzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Shyndec Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University Shenzhen Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study were to demonstrate comparable safety and efficacy of&#xD;
      Terconazole Vaginal Suppositories, 80 mg and fluconazole in the treatment of subjects with&#xD;
      severe vulvovaginal candidiasis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study were to demonstrate comparable safety and efficacy of Terconazole Vaginal&#xD;
      Suppository 80 mg inserted intravaginally once daily before bedtime for 6 consecutive days&#xD;
      and oral fluconazole 150mg at day 1 and day 4 in the treatment of subjects with severe&#xD;
      vulvovaginal candidiasis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mycological Cure 1</measure>
    <time_frame>Between day 7-14 after treatment, an average of 10 days</time_frame>
    <description>Based on candida culture</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mycological Cure 2</measure>
    <time_frame>Between day 28-35 after treatment, an average of 30 days</time_frame>
    <description>Based on Candida culture</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Vulvovaginal Candidiasis</condition>
  <arm_group>
    <arm_group_label>Terconazole Vaginal Suppository</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluconazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terconazole Vaginal Suppository</intervention_name>
    <description>Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days</description>
    <arm_group_label>Terconazole Vaginal Suppository</arm_group_label>
    <other_name>Tekangzuo Yindao Shuan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
    <description>orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.</description>
    <arm_group_label>Fluconazole</arm_group_label>
    <other_name>Diflucan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Vulvovaginal candidiasis infection is diagnosed, the symptoms evaluated using a&#xD;
             numerical rating system based on severity (absent=0; mild=1; moderate=2; severe=3)&#xD;
             with a minimum VVC Composite Signs/Symptoms score of 7&#xD;
&#xD;
          -  Subject completes the informed consent process&#xD;
&#xD;
          -  Subject agrees to take study medication when scheduled&#xD;
&#xD;
          -  Subject complies with all clinical trial instructions. Commits to all follow-up visits&#xD;
&#xD;
          -  Subject agrees to abstain from sexual intercourse from the time of randomization&#xD;
             through the first seven days immediately following treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  had any other sexually transmitted disease or gynaecological abnormality requiring&#xD;
             treatment&#xD;
&#xD;
          -  had a disease known to predispose to candidiasis such as diabetes mellitus, or were&#xD;
             receiving antibiotics or corticosteriods&#xD;
&#xD;
          -  had used antifungal medication in the week before entry; or&#xD;
&#xD;
          -  were expected to menstruate within seven days of the start of treatment&#xD;
&#xD;
          -  infected more than one candida species&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>48 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shangrong Fan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Shenzhen Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University Shenzhen Hosptal</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518036</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://mmy.oxfordjournals.org/content/early/2015/04/14/mmy.myv017.long</url>
    <description>Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/25877666</url>
    <description>Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis</description>
  </link>
  <results_reference>
    <citation>Li T, Zhu Y, Fan S, Liu X, Xu H, Liang Y. A randomized clinical trial of the efficacy and safety of terconazole vaginal suppository versus oral fluconazole for treating severe vulvovaginal candidiasis. Med Mycol. 2015 Jun;53(5):455-61. doi: 10.1093/mmy/myv017. Epub 2015 Apr 15.</citation>
    <PMID>25877666</PMID>
  </results_reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 30, 2014</study_first_submitted>
  <study_first_submitted_qc>July 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2014</study_first_posted>
  <results_first_submitted>August 20, 2019</results_first_submitted>
  <results_first_submitted_qc>October 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 23, 2020</results_first_posted>
  <last_update_submitted>October 22, 2020</last_update_submitted>
  <last_update_submitted_qc>October 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University Shenzhen Hospital</investigator_affiliation>
    <investigator_full_name>Shangrong Fan</investigator_full_name>
    <investigator_title>Prof of Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidiasis, Vulvovaginal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluconazole</mesh_term>
    <mesh_term>Terconazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>At Clinic</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Terconazole Vaginal Suppository</title>
          <description>Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days&#xD;
Terconazole Vaginal Suppository: Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days</description>
        </group>
        <group group_id="P2">
          <title>Fluconazole</title>
          <description>Orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.&#xD;
Fluconazole: orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Terconazole Vaginal Suppository</title>
          <description>Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days&#xD;
Terconazole Vaginal Suppository: Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days</description>
        </group>
        <group group_id="B2">
          <title>Fluconazole</title>
          <description>Orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.&#xD;
Fluconazole: orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
            <count group_id="B2" value="70"/>
            <count group_id="B3" value="140"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mycological Cure 1</title>
        <description>Based on candida culture</description>
        <time_frame>Between day 7-14 after treatment, an average of 10 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Terconazole Vaginal Suppository</title>
            <description>Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days&#xD;
Terconazole Vaginal Suppository: Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole</title>
            <description>Orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.&#xD;
Fluconazole: orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Mycological Cure 1</title>
          <description>Based on candida culture</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mycological Cure 2</title>
        <description>Based on Candida culture</description>
        <time_frame>Between day 28-35 after treatment, an average of 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Terconazole Vaginal Suppository</title>
            <description>Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days&#xD;
Terconazole Vaginal Suppository: Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole</title>
            <description>Orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.&#xD;
Fluconazole: orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Mycological Cure 2</title>
          <description>Based on Candida culture</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 35 after treatment</time_frame>
      <desc>Vulvovaginal pruritus, burning and irritation</desc>
      <group_list>
        <group group_id="E1">
          <title>Terconazole Vaginal Suppository</title>
          <description>Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days&#xD;
Terconazole Vaginal Suppository: Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days</description>
        </group>
        <group group_id="E2">
          <title>Fluconazole</title>
          <description>Orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.&#xD;
Fluconazole: orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Shangrong Fan</name_or_title>
      <organization>Peking University Shenzhen Hospital</organization>
      <phone>86755-83923333 ext 5502</phone>
      <email>fanshangrong@163.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

